公开(公告)号：US11466098B2

公开(公告)日：2022-10-11

申请号：US16740778

申请日：2020-01-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Bernhard Eckert ,  Michael Gerg ,  Johann Karl ,  Martin Kaufmann ,  Julia Riedlinger ,  Magdelena Swiatek-de Lange ,  Lars Hillringhaus ,  Klaus Hirzel ,  Marcus-Rene Lisy

IPC: C07K16/36 ,  G01N33/574 ,  G01N33/86

Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

公开(公告)号：US20180231557A1

公开(公告)日：2018-08-16

申请号：US15952731

申请日：2018-04-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Vinzent Rolny ,  Farshid Dayyani ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Julia Riedlinger ,  Felix Herth ,  Thomas Muley

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N33/57484 ,  G01N2333/4742 ,  G01N2333/70596

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

公开(公告)号：US20140219998A1

公开(公告)日：2014-08-07

申请号：US14251788

申请日：2014-04-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

IPC: G01N33/574

CPC classification number: G01N33/57488 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/475 ,  G01N2800/52

Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

公开(公告)号：US20230055005A1

公开(公告)日：2023-02-23

申请号：US17821937

申请日：2022-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Bernhard Eckert ,  Michael Gerg ,  Johann Karl ,  Martin Kaufmann ,  Julia Riedlinger ,  Magdelena Swiatek-de-Lange ,  Lars Hillringhaus ,  Klaus Hirzel ,  Marcus-Rene Lisy

IPC: C07K16/36 ,  G01N33/574 ,  G01N33/86

Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

公开(公告)号：US20160169895A1

公开(公告)日：2016-06-16

申请号：US15046525

申请日：2016-02-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Riedlinger ,  Markus Roessler ,  Michael Tacke

IPC: G01N33/573

CPC classification number: G01N33/573 ,  G01N33/54306 ,  G01N33/57411 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/57488 ,  G01N2333/922 ,  G01N2800/52 ,  G01N2800/7028 ,  G16H50/30 ,  Y02A90/26

Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.

公开(公告)号：US09116156B2

公开(公告)日：2015-08-25

申请号：US14022273

申请日：2013-09-10

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Julia Riedlinger

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6884 ,  G01N2333/4703 ,  G01N2800/122

Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ASC in said sample in vitro.

Abstract translation: 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质ASC来评估来自个体的样品的COPD的方法。

公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20160377625A1

公开(公告)日：2016-12-29

申请号：US15259392

申请日：2016-09-08

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

IPC: G01N33/574

CPC classification number: G01N33/57488 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/475 ,  G01N2800/52

Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

公开(公告)号：US20150056642A1

公开(公告)日：2015-02-26

申请号：US14533362

申请日：2014-11-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Julia Riedlinger ,  Markus Roessler

IPC: G01N33/68

CPC classification number: G01N33/6884 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2800/122 ,  G01N2800/60

Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro.

Abstract translation: 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质ARMET来评估来自个体的样品的COPD的方法。

公开(公告)号：US20160109461A1

公开(公告)日：2016-04-21

申请号：US14919456

申请日：2015-10-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Julia Riedlinger ,  Norbert Wild

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6884 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2800/122 ,  G01N2800/60

Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.

Abstract translation: 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质FEN1来评估来自个体的样品的COPD的方法。